Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of VB-201 in adults with elevated hsCRP
2010-020783-38Phase 2Completed
- Sponsor
- VBL Therapeutics
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VB-201 in chronic inflammation (7 arms), sponsored by VBL Therapeutics. Primary endpoint: Change from baseline of hsCRP levels. Started Aug 2010; status: completed.
02
Drugs
VB-201
03
Conditions
chronic inflammation
Beyond the preview
Go deeper on 2010-020783-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020783-38.